(Total Views: 322)
Posted On: 08/07/2019 11:33:41 AM
Post# of 154901
Share price is a reflection of being on OTC, financing and investor fatigue. No institutional investing, fear of bankruptcy or major dilution and investors who have been watching this not seeing a breakout. A lot of investors look for a 15%+ jump before buying in.
With BP it's a matter of not ponying up what this worth. Guaranteed Gilead's past offer was less than what one years revenue will become for combo only. At this point any offer is completely discounting cancer indications. Any BO offer that would be made by BP now should be turned down by Cytodyn.
BP's offers will probably always be trailing what the worth of the company is. By the time results for Phase 2 mTNBC trial is in their offer will reflect HIV and a small fraction of the cancer potential.
With BP it's a matter of not ponying up what this worth. Guaranteed Gilead's past offer was less than what one years revenue will become for combo only. At this point any offer is completely discounting cancer indications. Any BO offer that would be made by BP now should be turned down by Cytodyn.
BP's offers will probably always be trailing what the worth of the company is. By the time results for Phase 2 mTNBC trial is in their offer will reflect HIV and a small fraction of the cancer potential.
(2)
(0)
